NEW YORK (GenomeWeb News) – Helicos BioSciences reported after the close of the market Tuesday that its second-quarter revenues fell around 29 percent, as its grant and service revenues declined year over year.

The Cambridge, Mass.-based single molecule sequencing technologies firm had total revenues of $577,000 for the three months ended June 30, compared to $809,000 for the second quarter of 2011. Its service revenue fell to $175,000 from $273,000, and its grant revenue dropped to $243,000 from $427,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.